Nuvation Bio (NUVB)

Executive Summary

Nuvation Bio is a clinical-stage oncology company developing small molecule therapies targeting genetically defined cancers. Its lead asset, taletrectinib, is a next-generation ROS1/NTRK inhibitor in Phase 3 (TRUST-II) for ROS1-positive non-small cell lung cancer. The second key asset, safusidenib, is an IDH1 inhibitor in Phase 3 (SURPASS) for IDH1-mutant glioma. Both programs address validated targets but face competition from approved therapies such as entrectinib, repotrectinib, and vorasidenib. The company has streamlined its pipeline after discontinuing earlier-stage programs (NUV-422, AB-106). Nuvation Bio has sufficient cash runway through upcoming data readouts. The Phase 3 trials are large, randomized, and event-driven, with enrollment progress being a key near-term focus. Investors will watch for top-line efficacy and safety data that could support regulatory filings. Given the competitive landscape and execution risk, conviction is moderate.

Upcoming Catalysts (preview)

• H2 2027Taletrectinib Phase 3 (TRUST-II) topline data for ROS1+ NSCLC70% success
• H1 2027Safusidenib Phase 3 (SURPASS) interim efficacy data for IDH1-mutant glioma60% success
• TBDInitiation of NDA submission for taletrectinib (if data positive)50% success